New Family of OCT Products and New Eye Care Data Management Software Introduced at Annual Meeting of Ophthalmology
CHICAGO & DUBLIN, Calif. & JENA, Germany--(BUSINESS WIRE)--Nov 16, 2012--Medical technology manufacturer Carl Zeiss Meditec introduced a new family of OCT products spanning the full spectrum of multi-modality imaging for retinal disease and glaucoma at the 2012 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Asia-Pacific Academy of Ophthalmology (APAO) in Chicago. The company also announced receiving US FDA clearance for Software Version 3.0 of the FORUM®Eye Care Data Management System for streamlined clinical workflow and practice efficiency. Additionally the first 29 subjects in the US clinical trial for the VisuMax®ReLEx®smile procedure have been treated and the one month results for the first 15 subjects were presented at a ZEISS sponsored symposium during the Joint Meeting.
Introduction of new family of OCT products Carl Zeiss Meditec introduced a new family of CIRRUS OCT (Optical Coherence Tomography) products at the 2012 AAO-APAO Joint Meeting. The new OCT family is comprised of two CIRRUS™ HD-OCT models, the 5000 and 500, and two integrated multi-modality OCT and fundus imaging systems, the CIRRUS™ photo 800 and 600. The new modernized OCT platforms deliver clinical and workflow solutions that span the spectrum of care and address specific workflow and practice needs.
"The new CIRRUS family offers a choice of high-quality ZEISS OCT clinical solutions for the diagnosis and management of glaucoma and retinal disease across all levels of care, from comprehensive practices to advanced subspecialty practices," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "Practitioners can now benefit from diagnostic and workflow solutions that are tailored specifically for the level of care they provide, their practice workflow and their case load volumes. The new family of OCT products enables more practitioners to offer patients a high level of care and to tailor their investment to their workflow and practice needs." The CIRRUS HD-OCT 5000 is optimized for high-volume advanced care practices and is configured with the most sophisticated clinical applications, such as Advanced RPE Analysis and Ganglion Cell Analysis, and with precise measurement tools, such as new FastTrac™ retinal tracking, for rapid analysis and decision-making.
The CIRRUS HD-OCT 500, for comprehensive care practices, offers essential OCT capabilities with a broad range of clinical applications in an easy-to-learn, easy-to-use instrument for the management of glaucoma and retinal disease, retina assessment for cataract surgery, and anterior segment imaging for corneal disease.
The CIRRUS photo 600 and 800 combine standard-setting CIRRUS OCT technology with full-featured mydriatic/non-mydriatic fundus imaging into integrated, compact, multi-modality systems for flexibility and versatility.
The CIRRUS HD-OCT 5000 and 500 are immediately available for sale in the US and other markets. The CIRRUS photo 800 and 600 are to be released globally in early 2013.
For more information on the CIRRUS family, please go to: www.meditec.zeiss.com/press/cirrus-family.
US FDA clearance for software version 3.0 of FORUM Eye Care Data Managment system Carl Zeiss Meditec announced receiving US FDA clearance for software version 3.0 for the next version of their FORUM Eye Care Data Management system. FORUM enables eye care practitioners to centrally store exam data and images from various instruments – including the new family of CIRRUS HD-OCT and CIRRUS photo instruments – and to access them quickly and easily at any time. With the FORUM 3.0 multi-site practices and hospitals can easily and conveniently interchange data or view exam data from remote sites using the FORUM Viewer. Preconfigured Clinical Displays accelerate practice workflows through automatic loading and display of the relevant exam data for various eye pathologies.
The FORUM Eye Care Data Management system was on display in the ZEISS booth #534 during the Joint Meeting and was also exhibited at the AAO sponsored IHE Eye Care Multi-vendor Interoperability Showcase at the Electronic Office.
The latest advancements for CIRRUS HD-OCT and FORUM Eye Care Data Management was a focus of presentations of leading ophthalmologists at the ZEISS sponsored symposium “Energize Your Practice with New Diagnostics that Streamline Patient Care” on Saturday November 10, 2012 at the McCormick Place West, Conference Center.
For more information go to: www.meditec.zeiss.com/aao.
US Clinical Trial of new Minimally Invasive, All-Femto Laser Vision Correction Method Carl Zeiss Meditec announced that the first 29 subjects in the VisuMax IDE clinical trial in the US have been treated with the ReLEx smile procedure for the correction of spherical myopia with the VisuMax femtosecond laser. One month results for the first 15 subjects were presented during the AAO-APAO Joint Meeting at the ZEISS sponsored symposium “Next Frontier in Perfecting Corneal Refractive Surgery” by Jon Dishler, MD. Dr. Dishler is the Medical Monitor for the United States VisuMax clinical trial and the first study site to initiate treatments using the ReLEx smile procedure. Carl Zeiss Meditec received conditional approval from the US FDA to initiate the clinical trial in April 2012.
For more information on the symposium go to: www.meditec.zeiss.com/aao.
Please find more information about the US clinical trial at: www.meditec.zeiss.com/press/clinical-trial.
Book Launch of Perimetry Primer and Interpretation Guide Carl Zeiss Meditec and doctors, Anders Heijl, Vincent Michael Patella and Boel Bengtsson announced the global introduction of “Effective Perimetry –The Field Analyzer Primer” 4th edition during the 2012 AAO-APAO Joint Meeting. Introduced nearly 25 years ago, the Humphrey ® primer has become one of the most consulted perimetry interpretation guides in the world. Meeting attendees received a free copy of this educational guide. The authors were available for a complimentary book signing in the ZEISS booth.
For more information: www.meditec.zeiss.com/aao.
Routine Diagnostics Introduction Rounding off its diagnostic portfolio, Carl Zeiss Meditec introduced the VISUREF 100, a combination Autorefractor and Keratometer, during the Joint Meeting. This routine diagnostic instrument is fast, accurate, simple-to-use and fits easily into a practice's daily routine.
Attendees of the 2012 AAO-APAO Joint Meeting experienced ZEISS‘ state-of-the-art innovations and practice solutions at the ZEISS booth at McCormick Place South in Chicago.
Brief profile Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2010/11 (ended 30 September) the company's around 2,400 employees generated revenue of EUR 759 million.
The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. 35 percent of Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.
For more information, please go to: www.meditec.zeiss.comCONTACT: Contact for the press Carl Zeiss Meditec AG Jann Gerrit Ohlendorf, +49 36 41 220-331 Director Corporate Communications email@example.com or Contact for investors Carl Zeiss Meditec Henriette Meyer, Director Investor Relations www.meditec.zeiss.com/press KEYWORD: UNITED STATES EUROPE NORTH AMERICA CALIFORNIA ILLINOIS GERMANY INDUSTRY KEYWORD: TECHNOLOGY DATA MANAGEMENT SOFTWARE HEALTH OPTICAL SOURCE: Carl Zeiss Meditec Copyright Business Wire 2012 PUB: 11/16/2012 10:41 PM/DISC: 11/16/2012 10:41 PM http://www.businesswire.com/news/home/20121116006230/